Welcome to our dedicated page for Roche Hldg news (Ticker: RHHBY), a resource for investors and traders seeking the latest updates and insights on Roche Hldg stock.
Roche Holding Ltd. (RHHBY) reports healthcare developments across medicines, diagnostics and digital health, including updates from Genentech as a member of the Roche Group. Recurring news covers operating and financial results, regional sales trends, product performance and regulatory disclosures tied to the company’s pharmaceutical and diagnostic portfolios.
Company updates frequently feature ophthalmology products and pipeline assets such as Vabysmo, Susvimo and vamikibart across retinal conditions including diabetic macular edema and neovascular age-related macular degeneration. Roche also reports clinical data in neurology and autoimmune disease, including fenebrutinib in multiple sclerosis and ENSPRYNG in myelin oligodendrocyte glycoprotein antibody-associated disease, along with diagnostics approvals and patient-education initiatives.
Roche (OTCQX:RHHBY) reported that the US FDA accepted, under Priority Review, its New Drug Application for giredestrant, an oral SERD, as adjuvant therapy for adults with ER-positive, HER2-negative stage I–III breast cancer.
Phase III data showed a 30% iDFS risk reduction versus standard endocrine therapy (HR=0.70) and three-year iDFS of 92.4% vs 89.6%. The FDA decision (PDUFA date) is expected by 30 November 2026. Overall survival data remain immature but show a positive trend.
Roche (OTCQX:RHHBY) will present new Phase II data from its obesity portfolio at the American Diabetes Association’s 2026 Scientific Sessions.
Highlights include late-breaking efficacy and safety results for enicepatide (CT-388) and petrelintide, and plans for a Phase II fixed-dose combination trial starting around mid-2026.
Genentech (OTCQX:RHHBY) will present new Phase II obesity data at the American Diabetes Association’s 2026 Scientific Sessions. Late-breaking results cover enicepatide (CT-388), a dual GLP-1/GIP agonist, and petrelintide, a human amylin analog for weight management.
According to Genentech, both medicines show promising efficacy, safety and tolerability, are progressing toward Phase III, and will also be studied in a Phase II multi-arm fixed-dose combination trial starting around mid-2026. A virtual investor event is planned for June 8, 2026.
Roche (OTCQX:RHHBY) launched the Liver Disease Panel, a certified library of healthcare algorithms to support chronic liver disease (CLD) management. The suite includes the CE-marked LiverPRO algorithm from Evido, which uses age and routine blood biomarkers to assess liver fibrosis risk and guide earlier, non-invasive care.
According to Roche, the panel combines biomarkers such as Elecsys PRO-C3 with digital tools like ADAPT3 to support decisions from fibrosis risk identification through liver cancer surveillance, aiming to improve detection for a global CLD population of 1.5 billion people.
Genentech (OTCQX:RHHBY) will present new data at ASCO 2026 from nine approved and investigational medicines across more than 15 cancer indications.
Highlights include three Phase III trials of giredestrant in ER-positive/HER2-negative breast cancer, new HER2-positive and brain-metastasis–focused data, KRAS G12C lung cancer combinations, and updated lymphoma results.
Roche (OTCQX:RHHBY) will present new data at ASCO 2026 from nine approved and investigational cancer medicines across more than 15 indications.
Key updates spotlight giredestrant phase III breast cancer trials (lidERA, persevERA, evERA), HER2-positive brain-permeable TKIs, KRAS G12C lung cancer therapy divarasib, and novel lymphoma combinations.
Genentech (OTCQX:RHHBY) received FDA approval for Tecentriq and Tecentriq Hybreza as adjuvant treatment for adult muscle-invasive bladder cancer (MIBC) patients with ctDNA MRD after cystectomy, identified by Natera’s Signatera CDx assay.
This first ctDNA-guided therapy and Tecentriq’s 11th U.S. indication is supported by Phase III IMvigor011 data, where Tecentriq reduced risk of disease recurrence or death by 36% and risk of death by 41%, with a safety profile generally consistent with prior studies.
Roche (OTCQX:RHHBY) received a CE mark for its Elecsys pTau217 blood test, developed with Eli Lilly, to detect Alzheimer’s-related amyloid pathology.
The single-assay test is intended to rule in or rule out amyloid pathology across primary and secondary care using a routine blood draw, with accuracy reported as comparable to cerebrospinal fluid diagnostics against PET-CT scans.
Roche (OTCQX: RHHBY) agreed to acquire PathAI to expand its digital pathology and AI diagnostics capabilities. Roche will pay USD 750 million upfront plus up to USD 300 million in milestone payments. Closing is subject to customary conditions, including antitrust and regulatory approvals, and is expected in the second half of 2026. The acquisition will fold PathAI into Roche Diagnostics and aims to scale PathAI’s AISight Image Management System globally, combine AI-driven pathology with Roche’s companion-diagnostics expertise, and accelerate biomarker discovery, translational research, and clinical trial support.
Roche (OTCQX: RHHBY) will present more than 45 abstracts at ARVO 2026 (3–7 May), including 20 oral presentations across five retinal conditions. Key disclosures include real-world VOYAGER data showing 6 months of Vabysmo retinal drying, Susvimo sustained-delivery findings, and early phase 2 vamikibart results.
Presentations cover nAMD, DME, RVO, UME and geographic atrophy with multiple posters and oral sessions scheduled in Denver.